The severe course of the disease COVID-19, unknown until December 2019 is due to the phenomenon of “cytokine storm”, which means excessive release of proinflammatory biologically active substances by immunocompetent cells in response to infection with SARS-CoV-2 virus. Therefore, in the treatment of coronavirus pneumonia, in particular, glucocorticosteroids and other anticytokine drugs with anti-inflammatory effect are used.
Numerous scientific publications also indicate the effectiveness of umbilical cord and placental mesenchymal stem cells in the treatment of COVID-19. In recent years, mesenchymal stem cells of the umbilical cord and placenta have become widely used in the treatment of autoimmune diseases (Crohn’s disease, ulcerative colitis, multiple sclerosis, rheumatoid arthritis, etc), where immunosuppressive action is required. Also in the treatment of COVID-19 are studied T-lymphocytes of umbilical cord blood, as we reported earlier.
Today, COVID-19 cell therapy is being studied in more than 70 clinical trials in the United States, Canada, China, Brazil, Pakistan, Iran, Denmark, France, Italy, Germany, Belarus, and Ukraine. In Ukraine, the method of treatment of COVID-19 using mesenchymal stem cells of the umbilical cord and placenta was developed by scientists and doctors of the Institute of Cell Therapy, based on world experience in the treatment of coronavirus pneumonia and more than 50 years of experience in cell therapy.
To “keep finger on the pulse” in the field of modern anti-inflammatory therapy the representatives of the Institute of Cell Therapy on November 11, 2020, participated in the Boulder Peptide Symposium, dedicated to the anticytokine peptides. Due to quarantine restrictions, the meeting took place in a webinar format. Specialists of the Institute of Cell Therapy constantly introduce new knowledge gained at foreign congresses and within the framework of international research projects into the work of Cryobank and the Clinic.